Cyclosporine: A Review by Tedesco, Dustin & Haragsim, Lukas
Hindawi Publishing Corporation
Journal of Transplantation





Division of Nephrology and Hypertension, University of Oklahoma Health Sciences Center, 920 S. L. Young Blvd,
WP 2250 Oklahoma City, OK 73104, USA
Correspondence should be addressed to Dustin Tedesco, dustin-tedesco@ouhsc.edu
Received 14 July 2011; Accepted 28 October 2011
Academic Editor: Andreas Zuckermann
Copyright © 2012 D. Tedesco and L. Haragsim.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The discovery and use of cyclosporine since its inception into clinical use in the late 1970s has played a major role in the
advancement of transplant medicine. While it has improved rates of acute rejection and early graft survival, data on long-term
survival of renal allografts is less convincing. The ﬁnding of acute reversible nephrotoxicity and nephrotoxicity in nonrenal
transplants has since led to the widely accepted view that there is a chronic more irreversible component to this agent as well.
Since that time, there has been intense interest in ﬁnding protocols which seek to minimize and even avoid the use of calcineurin
inhibitors altogether. We seek to review cyclosporine in terms of its mechanism of action, pathophysiologic, and histologic features
associated with acute and chronic nephrotoxicity and recent studies looking to avoid its toxic side eﬀects.
1.Introduction
Discovered in the lab of Sandoz in Switzerland in 1972,
cyclosporine (CsA) has since revolutionized transplant
medicine. Initially discovered while searching for novel anti-
fungalagents,itwasfoundtohavemanyimmunologic prop-
erties that made it an attractive agent for immunosuppres-
sion following renal and other solid organ transplants. With
the premise that cell-mediated immunity was involved in
autoimmuneandchronicinﬂammatoryconditions,Borelset
upaseriesofexperimentsusingantiinﬂammatory,immuno-
suppressant, and antimitotic medications to examine their
eﬀects on lymphocyte-mediated lysis of presensitized and
na¨ ıve eﬀector cells. In these experiments, it was found that
cyclosporine inhibited both in vitro cell-mediated lysis as
well as lymphocyte sensitization by allogeneic target cells
[1]. It was this work and others by Borel that exhibited
the cell-mediated speciﬁcity of cyclosporine, theoretically
lending itself to a far better side eﬀect proﬁle than the
current immunosuppressive agents in use at that time. Sub-
sequently, a European multicenter trial demonstrated one-
year graft survival of 72% and 52% in recipients of cadaveric
renal transplants allocated to receive either cyclosporine or
azathioprine and steroids, respectively, for immunosuppres-
sion. Such promising results helped lead to clinical approval
of CsA for use in the early 1980s [2]. With improved rates
of acute rejection and one-year graft survival, cyclosporine
has become a mainstay for immune suppression of renal and
other solid organ transplants. A review from Hariharan et
al. published in 2000 looking at graft survival in more than
93,000 transplants from 1988 to 1996 revealed one-year graft
survival rates of 94 and 88% in living related and deceased
donor allografts, respectively [3] .T h em o s tr e c e n td a t af r o m
United Network for Organ Sharing (UNOS) from 1998 to
2007 reveals current one-year adjusted survival rates to be
96.6 and 91.6% in living related and deceased donor renal
allografts, respectively. Despite the marked improvement in
the rates of acute rejection and one-year graft survival, long-
term data has been somewhat disappointing, with current
age-adjusted graft survival at ﬁve years only 81.4% in living
related donors and 71.6% in those with deceased donor
transplants. This diﬀerence has largely been attributed to the
nephrotoxic eﬀects of cyclosporine.
That cyclosporine is nephrotoxic was discovered even
with its initial use. In the ﬁrst attempt at using cyclosporine
for immunosuppression following transplant, Calne et al.2 Journal of Transplantation
using a dose of 25mg/kg found a signiﬁcant but unexpected
nephrotoxicity that was not seen in initial animal experi-
ments [4]. Follow-up studies by the same group using a
slightly lower dose (17mg/kg) and selecting for primary
functioning allografts showed improved outcomes with this
new strategy with a one-year predicted graft survival rate
of 86% [5, 6]. Subsequent studies in which renal allograft
recipients who received CsA for 90 days were switched
to conventional treatment with azathioprine, and corticos-
teroids demonstrated improvement in renal function similar
to controls [7, 8]. Other studies have also demonstrated
improved GFR and blood pressure measurements using a
target of ﬁfty percent of the standard area-under-the-curve
(AUC) dose [9]. Thus, it appeared that CsA nephrotoxicity
may be dose dependent and reversible upon dose reductions
or discontinuation of the drug. Since that time, one of the
major reasons given for the lack of long-term improve-
ment in graft survival has been chronic calcineurin (CNI)
nephrotoxicity. While this has been the source of much
debate,theoverallattitudehasbeenoneofacceptance.Taken
together with its nephrotoxicity and other well-established
nonimmunologic side eﬀects, there is now strong interest
in creating calcineurin-free protocols for the prevention of
transplant rejection. This dates back historically, as early
as the 1990s in which the desire to reduce CsA exposure
without risking under immunosuppression led to protocols
including two other immunosuppressive agents. Taken a step
further was the use of antilymphocytic antibodies in the
early posttransplant period in an attempt to avoid early CsA
exposure altogether until such time that allograft function
was fully recovered [10].
2.StructureandClinicalPharmacology
Cyclosporine is a lipophilic, cyclic endecapeptide with a
molecular weight of 1202 Daltons [11] .I np l a s m a ,i ti s9 0 %
protein bound, mostly to lipoproteins, but also to albumin
and globulins. In blood, cyclosporine is extensively dis-
tributedinerythrocytes.Therearediﬀerencesinbioavailabil-
ity of cyclosporine in large part due to signiﬁcant interindi-
vidual variability in intestinal absorption, a process that
is further inﬂuenced by food ingestion, diabetes, gastric
motility problems, and diarrhea among other things [12].
However, variability in intestinal absorption is an eﬀect that
has been dampened by the creation of the microemulsion
formulations. Kovarik et al. demonstrated a more stable
concentration-time proﬁle and bioequivalent peak-trough
ﬂuctuationinbothfastingdaytimeandnonfastingnighttime
administration of the microemulsion formulation when
compared to that of the commercially available counterpart.
Furthermore, there was a 30% increase in AUC in the micro-
emulsion formulation due primarily to absorption-related
pharmacokinetic diﬀerences [13]. Metabolism is primarily
hepatic with a half-life of 6.4–8.7 hours with less than
1% appearing in the urine or feces. After metabolism
by the cytochrome P450 system, primarily CYP3A4, and
CYP3A5, CsA metabolites are eliminated in the bile with less
than 5% excreted in the urine. It is thought that variable
expression of the isoenzymes, CYP3A4, and CYP3A5 plays
a role in cyclosporine’s unpredictable bioavailability [12,
14]. Coadministration of medications known to inhibit
the cytochrome P-450 system (ketoconazole, erythromycin,
calcium-channel blockers, and others) is known to increase
cyclosporine levels. Likewise, inducers of the P-450 system,
such as phenytoin, phenobarbital, carbamazepine, and val-
proate, decrease cyclosporine levels [11].
3. Mechanismof Action
Calcineurin is a calcium/calmodulin-dependent serine thre-
onine protein phosphatase. Activated calcineurin dephos-
phorylates regulatory sites on several transcription factors,
most notably nuclear factor of activated T-lymphocytes
(NFATs).Inhibitionofcalcineurinbycyclosporineoccursvia
binding to the immunophilin, cyclophilin. It is this step that
prevents the dephosphorylation of NFAT and its subsequent
translocation from the cytoplasm to the nucleus in an IL-2-
mediated process. Inhibition at this level thereby prevents
activation of promoters of T-cell activation and overall
immune response.
In addition to its eﬀects on immune function, CsA pos-
sesses several other toxic eﬀects. The most notable is acute
and chronic nephrotoxicity, but also include hypertension,
hyperlipidemia, gingival hyperplasia, hyperkalemia, neuro-
toxicity, hypomagnesaemia, hyperuricemia, and thrombotic
microangiopathy [11]. These eﬀects are thought in part due
to calcineurin inhibition in nonlymphatic tissues [15]. The
electrolyte disturbances are believed due to alterations in
tubular function and thereby ion homeostasis [12, 16]. The
nephrotoxic eﬀects have garnered the most attention over
the years and have two components, an acute nephrotoxicity
caused by vascular dysfunction and a more chronic ﬁbrotic
form.
4.Pathophysiology ofCNI Nephrotoxicity
4.1. Acute Nephrotoxicity. The ﬁndings of nephrotoxicity in
early studies using CsA as an immunosuppressant led to
much research into the pathophysiology of this process.
Vasoconstriction of the aﬀerent arterioles was ﬁrst suggested
byMurrayetal.in1985,inwhichconsciousratswereadmin-
istered CsA infusions (20mg/kg) resulting in a signiﬁcant
reduction in renal blood ﬂow and a rise in renal vascular
resistance. This was proposed due to activation of the renal
sympathetic nervous system as there was demonstration of
a concomitant stimulation of plasma renin activity. Also
noted was a reduction in the rate of decline of renal
blood ﬂow in denervated rats [17]. Similarly, Barros et al.
demonstrated increase in vascular resistance in aﬀerent and
eﬀerent arterioles with a reduction in renal plasma ﬂow and
GFR, an eﬀect that was attenuated by pretreatment with
the angiotensin-converting enzyme inhibitor captopril and
the calcium channel blocker, verapamil [18]. This vascular
mediated eﬀect stems from an imbalance in vasoconstrictor
and vasodilator factors. Cyclosporine has been shown to
increase the vasoconstrictor factors endothelin as well asJournal of Transplantation 3
thromboxane in addition to its activation of the renin-
angiotensin system (RAS). Also demonstrated is a reduction
in the vasodilator factors, prostacyclin, prostaglandin E2,
and NO [19, 20]. Activation of the RAS by CsA is by two
mechanisms, a direct eﬀect on juxtaglomerular cells (JG)
and indirectly through arterial vasoconstriction and reduced
renal plasma ﬂow. The direct eﬀect of CsA on JG cells
was demonstrated in the late 1980s by Kurtz et al. In this
study, primary cell cultures from rat renal cortex containing
JG cells showed a threefold increase in renin secretion
upon exposure to cyclosporine. Furthermore, no increase in
prostaglandin formation or increase in cyclic AMP concen-
tration was observed. This led to the conclusion that CsA-
stimulated renin secretion by direct eﬀects on JG cells [21].
Another interesting observation in the potential pathogenic
mechanisms of vasoconstriction is that by H¨ ocherl et al.
who demonstrated that CsA markedly lowered COX-2
expression which has been shown to have binding sites
for NFAT. Therefore, the inhibition of calcineurin by CsA
leads to a reduction in NFAT-mediated COX-2 expression
and downstream production of arachidonic acid metabolites
thereby favoring vasoconstriction [22]. Other mechanisms
have been proposed as well including the demonstration
that CsA leads to mesangial cell contraction with subsequent
alterations in glomerular permeability, endothelin dysfunc-
tion, production of oxygen-free radicals and superoxide,
and interference with normal tubular function as previously
mentioned [23].
The role of the innate immune system has also been
implicated in the nephrotoxicity of CsA. Recent reports
suggest that upregulation of toll-like receptors (TLR) and
TNF-α, responsible for dendritic cell maturation, may be
stimulated by endogenous, noninfectious ligands (i.e.,
injured tubular epithelial cells) and stimulates secretion of
chemokines that initiate phagocytic inﬂux and immune
activation. A study done by Lim et al. demonstrated through
RT-PCR upregulation of TLR2, TLR4, and TNF-α mRNA
in CsA-treated rats. They also demonstrated increased levels
of MHC-II by immunohistochemistry. Thus, it may be
reasonable to conclude that activation of TLR2 and TLR4
by injured renal tubular cells caused by CsA provides a link
between innate immunity and the direct toxic eﬀects of CsA
on renal tubular cells [24].
4.2. Chronic Nephrotoxicity. The most notably referenced
study linking cyclosporine with chronic nephrotoxicity was
that done in 1984 by Myers et al. in which recipients of
cardiac transplants surviving greater than 12 months and
treated with CsA were compared to a similar group trans-
plantedpriorto1980whoreceivedazathioprineandsteroids.
Data at one month and out to one year revealed signiﬁcant
reductions in GFR, renal plasma ﬂow, and renal blood ﬂow.
Also, biopsy of ﬁve CsA-treated patients revealed tubuloint-
erstitial injury and focal glomerular sclerosis, the intensity of
which appeared to correlate with degree of renal impairment
[25]. Further evidence for chronic nephrotoxicity related to
long-term cyclosporine use is the clinical and pathologic
ﬁndings of impaired renal function in heart, liver, and lung
transplants as well as patients with autoimmune disease
treated with cyclosporine [26–29].
5.Pathologic Findings
The hallmark ﬁnding in CNI nephrotoxicity is arteriolar
hyalinosis,whichischaracterizedbynodularhyalinedeposits
in the tunica media of aﬀerent arterioles. Another com-
monly described ﬁnding is that of interstitial or so-called
striped ﬁbrosis. This is hypothesized to be secondary to
the aforementioned vasoconstrictive eﬀects of CsA with
subsequent arteriolar luminal narrowing. The subsequent
tissue ischemia/hypoxia leads to a reperfusion type injury
with the formation of reactive oxygen species and free
radicals leading to cellular injury and apoptosis [12, 23].
Cyclosporine has also been shown to upregulate TGF-β
expression in juxtaglomerular cells. TGF-β is known to
promote ﬁbrosis through its increase in the production
of extracellular matrix proteins and induction of epithelial
mesenchymal transition [12, 30].
ActivationoftheRASappearsimportantforthedevelop-
ment of CNI nephrotoxicity not only for its vasoconstrictive
eﬀects but also proinﬂammatory and proﬁbrogenic eﬀects.
This is thought due to the action of angiotensin II which has
been shown to induce ﬁbrosis mostly through induction of
TGF-β [12, 31, 32].
Perhaps, the most well-known study documenting the
long-term nephrotoxic eﬀects of cyclosporine and its asso-
ciated pathologic ﬁndings is that by Nankivell et al. in 2004.
The authors attempted to look at the histologic evolution of
CsA nephrotoxicity by examining protocol kidney biopsies.
Biopsy was performed at the time of implantation, again at
weeks one, two, and four and then months three, six, and
twelve, then yearly thereafter for ten years. In total, 888 study
biopsies were obtained in 99 patients yielding eight biopsies
per patient. At ten years, the point prevalence for lesions
considered to be consistent with chronic cyclosporine toxi-
city was 100%. Importantly, other causes of hyalinosis were
ruledoutincluding donor hyalinosis, hypertension,ischemic
injury, dyslipidemia, and hyperglycemia. The authors con-
cluded from this work that long-term immunosuppression
with CsA was inappropriate for renal transplant recipients
and that strategies for avoidance of calcineurin inhibitors be
validated[33].Whilestudieswerealreadyinprogresslooking
at ways to avoid or minimize exposure of renal allograft
recipients to the eﬀects of CNI, the study by Nankivell
seemed further validation.
6.Calcineurin-Inhibitor-SparingProtocols
6.1. Calcineurin Inhibitor Avoidance. One of the earliest
studies attempting to avoid CNI was that by Vincenti et al. in
which 98 patients receiving either cadaveric or living donor
kidneys received daclizumab (an IL-2 receptor blocker) plus
mycophenolate mofetil (MMF) and corticosteroids. Results
on primary eﬃcacy revealed unacceptably high rates of
biopsy-proven rejection (48% at 6 months) [34]. Addition-
ally, Larson et al. found no diﬀerence at one year in either4 Journal of Transplantation
patient or allograft survival nor incidence of acute rejection
using sirolimus along with MMF and corticosteroids [35].
6.2. Calcineurin Inhibitor Avoidance and/or Withdrawal.
More recently, three large studies have been published exam-
ining this topic. In December 2007, the ELITE-SYMPHONY
study examined 1645 renal transplants patients who were
designated to receive either standard therapy with CsA,
MMF, and corticosteroids or undergo daclizumab induction
MMF and corticosteroids and either low-dose tacrolimus,
low-dose CsA, or low-dose sirolimus. The primary endpoint
was GFR at 12 months. Results showed that patients in the
low-dose tacrolimus group had better GFR, highest graft
survival,andlowestrateofbiopsy-provenrejection. Thiswas
followed by the low-dose CsA group. The group receiving
low-dose sirolimus had worse outcomes and more serious
adverse events [36].
Similarly, the CAESAR study by Ekberg et al. used a
regimen of daclizumab induction followed by MMF and
corticosteroids and either CsA withdrawal by six months,
low-dose CsA (trough 50–100ng/mL) for 12 months, or
standard CsA (target trough 150–300ng/mL) for 12 months.
Mean GFR at 12 months (primary end point) did not
diﬀer signiﬁcantly among the three groups. However, rates
of biopsy-proven rejection were signiﬁcantly higher in the
CsA withdrawal group [37]. Followup to the CAESAR
study examining the pharmacokinetics of mycophenolic acid
(MPA) in relation to cyclosporine revealed higher MPA
AUC in the cyclosporine group as a result of enterohepatic
recirculation.Despitethisincrease,itwassuggestedthatdose
adjustments be made in MMF in the absence of CsA to avoid
underexposure and risk of acute rejection [38].
Finally, the BENEFIT study in 2010 examined the eﬀects
of the costimulation blocker belatecept versus cyclosporine
in preservation of renal function in living or deceased
donor renal transplants. Patients receiving either a more or
less intense regimen of belatacept experienced better renal
function and overall patient/graft survival but had higher
incidence and grade of acute rejection [39].
Taken together, the above studies demonstrate that while
attempts at minimizing or avoiding CNI altogether have
resulted in similar patient and allograft survival, rates of
acute rejection may be too great for the adoption of these
protocols on a routine basis. Similarly, one should use
caution in consideration of steroid-sparing protocols. While
short and intermediate outcomes show equivalent patient
and graft survival, long-term results may be less promising.
The presence of interstitial ﬁbrosis and tubular atrophy
may in fact be greater in steroid-free patients leading to
decreased long-term graft function. In addition, although
discontinuation of steroid therapy early after transplant may
reduce the risk of rejection, there are no studies evaluating
diﬀerent times in the ﬁrst year at which steroid therapy can
safely be discontinued [40].
While the toxic side eﬀect of acute nephrotoxicity as a
result of cyclosporine administration has been well docu-
mented and widely accepted, the concept of chronic nephro-
toxicity seems a matter still up for debate. Several issues
have been raised lately by opponents of this idea. First,
the histologic lesions thought characteristics of chronic CNI
nephrotoxicity are nonspeciﬁc. The ﬁndings of arteriolar
hyalinosis can also be seen with preexisting donor injury,
age, hypertension, and diabetes, as can the ﬁndings of
interstitial ﬁbrosis, tubular atrophy, and glomerulosclerosis.
The ﬁndings of tubular microcalciﬁcation can also be seen
with preexisting donor injury, ischemic tubular injury,
proteinuria, and acute tubular necrosis. In addition, many of
theaboveﬁndingscanbeseenwithrecurrenceoftheprimary
disease. Thus, when evaluating late deterioration in allograft
function, one must rule out several other common causes
before labeling it as chronic CNI toxicity [12]. Furthermore,
several of the studies mentioned above evaluating CNI
avoidance or sparing have failed to prove long-term beneﬁt
[41].Infact,inthemajority ofthestudiesalready mentioned
in this review, the authors found either no diﬀerence in
outcomes or found that those in the CNI avoidance group
had the worst outcomes, usually in regards to rates of
acute rejection. In a retrospective analysis of 1663 kidney
transplant patients, no correlation was found with CsA levels
and change in serum creatinine (SCr) or episodes of acute
rejection (although higher rejection rates were seen with
lower CsA doses at four to six months) over 36 month
followup. Moreover, they found no evidence of progressive
nephropathy with cyclosporine and concluded that graft loss
was most commonly due to acute rejection and chronic
graft dysfunction [42]. Looking again at the previously
mentioned study by Nankivell et al. , opponents point out
that while histologic abnormalities developed, the 10-year
death-censoredgraftsurvivalratewas95%andthemeanSCr
was 1.6mg/dL [33]. Moreover, the same group has published
a report in which MMF was used in place of azathioprine,
along with CsA and corticosteroids. Findings demonstrated
less interstitial ﬁbrosis, striped ﬁbrosis, glomerulosclerosis,
and mesangial matrix accumulation, lesions previously
attributed to long-term use of CNI. They also reported
decreased rates of acute rejection and delayed expression of
CsA nephrotoxicity [41, 43]. Overall, this suggests factors
other than cyclosporine alone contribute to chronic allograft
dysfunction. Additional ﬁndings calling into question the
signiﬁcance of chronic calcineurin exposure to late graft
failure are those of the DeKAF study. Results of this study
inwhichonehundredseventy-threerenaltransplantpatients
withlategraftfailureunderwentbiopsyshowedthatevidence
of antibody-mediated rejection was common and that risk of
graft loss was greatest in those with C4d+ staining. Diagnosis
of calcineurin inhibitor nephrotoxicity did not impact the
risk of late graft failure in this study [44].
What about data on renal function in nonrenal trans-
plants? As mentioned above, Myers et al. demonstrated
reduced GFR, renal plasma ﬂow, and renal blood ﬂow in
native kidneys of cardiac transplant recipients. Opponents
are quick to point out that the average dose of CsA was quite
high at 17.5mg/day with trough levels ranging from 300 to
350ng/dL for the ﬁrst four months following transplant and
were still 164ng/mL out to two years [25, 41].
More recently, Ojo et al. reviewed the incidence of
chronic renal failure and associated risk factors in nonrenalJournal of Transplantation 5
transplant patients in the US from 1990 to 2000. Results
indicated the greatest risk for development of chronic
renal failure were increasing age, female sex, pretransplant
hepatitis C, hypertension, diabetes, and postoperative renal
failure. Use of CNI was not found to be a signiﬁcant cause
[45]. Similarly, previous reports examining early surveillance
biopsies for predictors of renal allograft dysfunction have
shown that biopsies with active inﬂammation have worse
graft function after one year. Importantly, in these studies,
there was no correlation between use of CNI or CNI levels
and allograft function [46–48]. The above suggests that low-
level alloreactivity with subclinical rejection is likely another
factor in late allograft dysfunction.
Finally, if cyclosporine (and tacrolimus) is responsible
for chronic nephrotoxicity, why are some patients seemingly
immune to its eﬀects? As mentioned earlier, there is large
interindividual variability in many of the pharmacokinetic
properties of cyclosporine. However, studies do exist in non-
renal transplants where CsA exposure has been minimized
or CsA withdrawn altogether using replacement with MMF
or a combination of Everolimus and low-dose CsA showing
noninferiority with respect to renal function and rates of
acute rejection [49]. Furthermore, a study by Dharancy
et al. demonstrated a signiﬁcant increase in eGFR in liver
transplant patients switched from a CNI-containing regimen
to MMF monotherapy ﬁve years after liver transplant
with correspondingly low rates of rejection suggesting CNI
avoidance can and possibly should be considered [50].
More speciﬁc in regards to the aforementioned interindi-
vidual variability in pharmacokinetics is the role of drug
transporters and drug metabolizing enzymes. Hesselink et
al. recently reviewed the role of the drug transporter adeno-
sine triphosphate-binding cassette protein B1 (ABCB1) and
the enzymes of the cytochrome P450 system, speciﬁcally
CYP3A4 and CYP3A5.
ABCB1 is a 170kDa ATP-dependent drug transporter
responsible for transporting drugs from the cytoplasm to
the cell surface and ultimately into the extracellular space.
In human kidneys, ABCB1 is found most prominently in
the brush border of proximal tubular epithelial cells. ABCB1
has been shown to be upregulated in the setting of CsA
exposure, which likely serves as a protective mechanism
against CsA exposure. Likewise, demonstration of lower
ABCB1 expression has been shown to be a risk factor for
development of chronic histologic changes in CNI-treated
renal allograft recipients [14, 51].
CYP3A4 and to a larger extent CYP3A5 are the major
isoenzymes responsible for the hepatic metabolism of cy-
closporine. Studies have shown reduced intrarenal expres-
sion of CYP3A5 in renal biopsies which may be a risk
factor for nephrotoxicity in patients treated with CNI [14,
52]. Genetic associations examining the eﬀects of single
nucleotide polymorphisms (SNPs) suggest little role in
regards to CNI pharmacokinetics. Renal transplant patients
carrying the CYP3A5∗3 allele appear to require lower doses
of CNI to achieve target concentrations [53]. In regards
to ABCB1, studies have demonstrated that donor genotype
ABCB1 3435 TT is associated with CNI nephrotoxicity
and higher grades of IF/TA [44, 54]. Conversely, other
studies failed to demonstrate a correlation between allograft
survival and ABCB 1 genotype [55]. Even fewer data are
available for the role of genetic variation in CYP3A and CNI-
associated renal dysfunction. One study suggested biopsy-
proven tacrolimus nephrotoxicity in renal allograft recipi-
ents with CYP3A4∗1/CYP3A5∗1 and CYP3A4∗1B/YP3A5∗1
genotypes [56]. Conversely, subsequent studies have found
no signiﬁcant association with CYP3A5 genotype and CNI-
mediated nephrotoxicity [57]. Overall, data on this subject
are conﬂicting. Importantly, to date, there is no direct
evidence of higher intrarenal CNI concentrations as a
result of certain ABCB1 expression/genotype leading to CNI
nephrotoxicity [14]. Further study in this area is warranted.
With large interindividual variability in CsA pharma-
cokinetics, the known diﬀerence in allograft function and
subsequent survival with respect to living versus deceased
donor donation, and the availability of a greater number of
immunosuppression agents, it is clear that immunosuppres-
sive treatment should be individualized to each patient, even
if this means the possibility of CNI avoidance.
7. Summary
Cyclosporine has no doubt revolutionized transplant med-
icine since its ﬁrst clinical use in the late 1970s, improving
rates of acute rejection and early graft survival. Despite
the early discovery of acute, and more recently suggested
chronic nephrotoxicity, the use of CNI continues to be a
mainstay in transplant medicine. While the latter concept is
still being actively debated, the nonimmunologic side eﬀects
of the calcineurin inhibitors cyclosporine and tacrolimus
warrantcontinuedresearchintoeﬀectiveprotocolsachieving
fewer side eﬀects while maintaining low risk of rejection.
While data in this regard are promising, none appears so
overwhelming so as to supplant CNI as a treatment for the
prevention of transplant rejection.
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